Is Bajaj Healthcare a Good Buy After Its Q1 FY27 Results?

The Bajaj Healthcare share price has been under the spotlight this results season after the company reported its first-quarter numbers for FY27. Bajaj Healthcare is a pharmaceutical company manufacturing active pharmaceutical ingredients and formulations, and its Q1 FY27 print, for the quarter ended June 30, 2026, gives investors a fresh data point to test whether the stock still deserves a place in a portfolio at current levels.

Revenue for the quarter came in at Rs 166 crore, up 11.3% year on year, while profit after tax came in at Rs 14 crore, up 15.8% from a year earlier. That combination of numbers is exactly what this article breaks down, along with what it means for the Bajaj Healthcare share price from here.

This piece works through the quarter's financial highlights, the business factors behind the numbers, where the Bajaj Healthcare share price stands against its 52-week range and valuation multiples, and the key risks worth watching before treating this as a buy, hold or a stock to avoid for now.

Click Here – Get Free Investment Predictions

Bajaj Healthcare Q1 FY27 Financial Highlights

Metric	Q1 FY27	Q1 FY26	YoY Change
Revenue	Rs 166 crore	Rs 149 crore	11.3%
EBITDA	Rs 30 crore	Rs 25 crore	16.4%
Operating Margin	17.8%	17.0%	NA
Net Profit / (Loss)	Rs 14 crore	Rs 12 crore	15.8%

Bajaj Healthcare Q1 FY27 Performance Analysis

Check Bajaj Healthcare Fundamentals on Univest Screener

Revenue growth of 11.3% for the quarter came from steady demand across the company's core business, keeping the topline trend intact for the active pharmaceutical ingredients and formulations sector.

The bigger story is on profitability. PAT grew 16% to Rs 14 crore, comfortably ahead of revenue growth, which points to margin expansion or a favourable base effect. This is the kind of quarter that supports the premium the Bajaj Healthcare share price already commands, though investors should check whether the growth is repeatable or was helped by one-off factors.

Sequential quarterly data was not fully available for this comparison, so investors should track the next quarter's results to build out the trend behind the Bajaj Healthcare share price.

Key Business Factors in Q1 FY27

Revenue Trend

Bajaj Healthcare's revenue grew 11.3% year on year this quarter, taking the quarterly base to Rs 166 crore in a active pharmaceutical ingredients and formulations business that remains sensitive to demand and pricing cycles that ultimately feed through to the Bajaj Healthcare share price.

Margin Movement

EBITDA rose 16.4% to Rs 30 crore, and operating margin moved to 17.8% from 17.0% a year earlier, a sign that cost control or pricing held up during the quarter.

Balance Sheet Position

Bajaj Healthcare's debt-to-equity ratio stands at 0.47, a level worth monitoring given the quarter's margin trend.

Valuation Context

The stock trades at a PE of 62.8x against an industry average of 51.4x, a premium that this quarter's results will need to justify going forward.

Dividend Details

No interim dividend was declared alongside Bajaj Healthcare's Q1 FY27 results. The stock currently carries a trailing dividend yield of 0.46%, based on dividends paid over the last year. Investors tracking the Bajaj Healthcare share price for income should watch the company's announcements around its next annual results for any dividend decision.

Bajaj Healthcare Share Price Outlook for FY27

The Q1 FY27 print sets a reasonably high bar for the rest of the year. If Bajaj Healthcare can sustain this pace of revenue and profit growth, the current valuation gets easier to justify. The main swing factor is whether this quarter's momentum reflects a durable trend or a favourable one-off, something the next two quarters should clarify.

For the Bajaj Healthcare share price to hold its current premium through FY27, the company will likely need to keep posting growth at or near this quarter's pace, since any slowdown would put pressure on a stock priced for continued strength.

Bajaj Healthcare Stock Performance

Download the Univest iOS App or Univest Android App to track Bajaj Healthcare's live share price and get daily stock updates.

The Bajaj Healthcare share price was trading around Rs 329 as results season played out in late August 2026, roughly 36.2% below its 52-week high of Rs 516 and well above its 52-week low of Rs 272. Promoter holding stood at 58.6% as of the June 2026 quarter.

The Bajaj Healthcare share price has room to re-rate further if the growth shown this quarter continues, though much of the good news may already be reflected in the stock near current levels. On profitability ratios, the company reports a return on equity of 8.81% and a book value of around Rs 158 per share, both useful reference points when judging whether the current price is reasonable.

Key Risks

Valuation Risk

At 62.8x earnings against an industry average of 51.4x, the stock leaves little room for disappointment if growth slows.

Sector and Demand Risk

As a active pharmaceutical ingredients and formulations business, Bajaj Healthcare's results remain tied to sector-specific demand, pricing and regulatory cycles that can shift from quarter to quarter and move the Bajaj Healthcare share price well before the next result.

Execution Risk

Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

Conclusion

Bajaj Healthcare's Q1 FY27 results were genuinely strong, with revenue at Rs 166 crore and PAT up 16% to Rs 14 crore. That said, at a PE of 62.8x, the Bajaj Healthcare share price is not inexpensive, so this looks like a quality business trading at a full price rather than a bargain. Existing investors have little to worry about from this print, while new investors asking whether Bajaj Healthcare is a good buy should weigh the strong quarter against the valuation before adding at current levels.

Frequently Asked Questions on Bajaj Healthcare Q1 FY27 Results

What were Bajaj Healthcare's Q1 FY27 results?

Ans. Bajaj Healthcare reported Q1 FY27 revenue of Rs 166 crore, up 11.3% year on year, and PAT of Rs 14 crore, up 15.8% year on year.

Is Bajaj Healthcare a good buy after its Q1 FY27 results?

Ans. Bajaj Healthcare's core numbers improved this quarter, though at a PE of 62.8x the stock is not inexpensive, so this suits investors comfortable paying up for quality. Investors should form their own view based on their own risk appetite and time horizon.

What is the Bajaj Healthcare share price today?

Ans. The Bajaj Healthcare share price was trading around Rs 329 in late August 2026, about 36.2% below its 52-week high of Rs 516 and well above its 52-week low of Rs 272.

What is Bajaj Healthcare's revenue and profit for Q1 FY27?

Ans. Bajaj Healthcare reported revenue of Rs 166 crore and a net profit of Rs 14 crore for the quarter ended June 30, 2026.

Did Bajaj Healthcare declare a dividend with its Q1 FY27 results?

Ans. No interim dividend was declared alongside Bajaj Healthcare's Q1 FY27 results. Investors should track the company's next annual results for any dividend announcement.

What is Bajaj Healthcare's PE ratio and is it expensive?

Ans. The Bajaj Healthcare share price trades at a trailing PE of 62.8x, against an industry average of 51.4x. Investors should compare this with the company's growth rate before judging value.

What are the key risks for Bajaj Healthcare investors right now?

Ans. At 62.8x earnings against an industry average of 51.4x, the stock leaves little room for disappointment if growth slows. Sustaining this quarter's trend into the rest of FY27 depends on management execution on costs, pricing and demand, none of which are guaranteed.

What is Bajaj Healthcare's promoter shareholding?

Ans. Promoter holding in Bajaj Healthcare stood at 58.6% as of the June 2026 quarter.